Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: SVY

COVID Vaccine-Hesitant Consumers Care About Effectiveness Over Side-Effects


SYDNEY, May 7, 2021 /CNW/ -- Market research software company Conjoint.ly today released results from its recent Consumer Preferences for COVID-19 Vaccine conjoint analysis survey, revealing that vaccine-hesitant consumers in the UK and US are most likely to be swayed by a fully-subsidised vaccine that has at least 85% effectiveness - comparable to results from a similar Chinese study.

Conjoint.ly's research, conducted between 31 March and 5 April 2021, takes inspiration from academics Leng et al's January 2020 conjoint study Individual preferences for COVID-19 vaccination in China, which also found that Chinese respondents are more willing to take the vaccine if it is free and highly effective.

"Countries around the world face similar challenges with vaccine rollouts. We were intrigued by conjoint research from China around factors of vaccine adoption. Our research showed that communicating vaccine effectiveness works well to convince people to take the jab in the West, as it does in the East," said Conjoint.ly's Founder, Nik Samoylov.

Both studies assessed respondents' vaccine preferences based on several factors, such as effectiveness and accessibility to determine which vaccine characteristics would encourage the highest uptake rates in each country. The conjoint surveys also presented respondents with choices surrounding risk of side-effects, duration of protection, number of doses required, and number of acquaintances already vaccinated.

About Conjoint.ly: Conjoint.ly is an online service for pricing and product research using state-of-the-art discrete choice methods (conjoint analysis), Van Westendorp, Gabor-Granger, monadic concept testing, and other techniques. Conjoint analysis is a popular market research methodology which helps to reveal consumers' preferences by presenting respondents with several product concepts much like in a real-life setting.

Catherine Chipeta, Conjoint.ly
Phone: +61-416-504-345
Email: [email protected]

Further information: https://conjointly.com/blog/covid-vaccine-consumer-survey

Related Files

202103_March_Omnibus_COVID-19_Consumer_Preferences[1].pdf

Related Images

vaccine-attribute-importance-for.png
Vaccine attribute importance for UK and USA consumers
The Conjoint.ly study found the most important attributes to be high vaccine effectiveness, low risk of side effects and a long period of protection - even among vaccine-hesitant people in UK and USA.

 

SOURCE Conjoint.ly


These press releases may also interest you

at 18:30
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

at 18:23
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...



News published on and distributed by: